Eos Inhibitors
Eos Inhibitors comprise a diverse group of chemicals that, through their specific biochemical actions, can indirectly modulate the activity or expression of the Eos protein by influencing related cellular signaling pathways. These inhibitors are characterized by their targeted interactions with key enzymes and receptors within the cell, resulting in the modulation of various signaling cascades.
The primary feature of Eos Inhibitors is their specificity in targeting crucial enzymes and receptors in cellular signaling. For instance, compounds like Wortmannin and LY3214996 specifically inhibit key kinases in the PI3K/AKT and MAPK/ERK pathways, respectively. This targeted inhibition leads to changes in downstream signaling, potentially affecting proteins regulated by these pathways, including Eos. Similarly, inhibitors such as Imatinib and Nilotinib, known for their tyrosine kinase inhibitory activity, can modulate signaling pathways related to cell growth and differentiation, thereby influencing proteins associated with these processes. Another significant aspect of Eos Inhibitors is their potential to affect multiple signaling pathways due to their broad or overlapping target profiles. Broad-spectrum inhibitors like Dasatinib can influence a range of kinases, thereby affecting various signaling pathways simultaneously. This wide-ranging action can lead to complex interactions within cellular signaling networks, potentially impacting the function or expression of proteins like Eos.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, it can modulate AKT signaling pathways, potentially affecting proteins involved in these pathways through changes in downstream signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, it affects cellular responses to stress and cytokines, potentially influencing protein activities within these pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the transforming growth factor-beta (TGF-beta) type I receptor kinase. It can modulate TGF-beta signaling, impacting cellular processes like growth and differentiation, thereby influencing protein activities. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is an ERK1/2 inhibitor, directly affecting the MAPK/ERK pathway. Its role in this pathway can modulate various protein activities, including those involved in cell proliferation and apoptosis. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It affects B-cell receptor signaling, potentially influencing proteins involved in B-cell development and function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor, primarily targeting BCR-ABL, c-KIT, and PDGF receptors. By modulating these pathways, it can influence protein activities and cellular responses related to growth and differentiation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib is another tyrosine kinase inhibitor with a target profile similar to Imatinib, primarily affecting BCR-ABL and PDGF receptor signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It disrupts protein degradation pathways, potentially affecting the stability and function of various proteins within the cell. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR inhibitor, affecting both mTORC1 and mTORC2 complexes. It can influence cellular processes such as growth, proliferation, and survival, potentially impacting proteins associated with these processes. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a BCL-2 inhibitor, influencing apoptotic pathways. It can modulate protein activities involved in cell death and survival mechanisms. | ||||||